Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab intraocular injection for neovascular glaucoma
ChiCTR-ONC-13003646Phase 4Completed
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Oct 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in neovascular glaucoma (NVG), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Intraocular pressure. Started Oct 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular glaucoma (NVG)
Beyond the preview
Go deeper on ChiCTR-ONC-13003646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-13003646.